Ascensia Diabetes Care And Senseonics Announced That Medicare Has Expanded Access To Eversense E3 CGM System, With Implementation Of Local Coverage Determinations To Access Implantable CGM For Basal-Only Patients, By First Three Medicare Contractors
Portfolio Pulse from Benzinga Newsdesk
Ascensia Diabetes Care and Senseonics announced that Medicare has expanded access to the Eversense E3 CGM System for basal-only patients, following the implementation of Local Coverage Determinations by the first three Medicare contractors. This expansion could significantly increase the user base of the Eversense E3 CGM System, potentially boosting Senseonics' market presence and financial performance.
February 12, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medicare's expanded access to the Eversense E3 CGM System for basal-only patients could significantly increase Senseonics' user base, potentially improving its market presence and financial performance.
The expansion of Medicare coverage to include the Eversense E3 CGM System for basal-only patients directly impacts Senseonics by potentially increasing its product's user base. This could lead to higher sales and revenues, improving the company's financial health and market position. Given the significance of Medicare as a payer in the healthcare system, this decision is likely to have a positive short-term impact on Senseonics' stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90